Merck unveils Phase 3 data for BELSOMRA C-IV in treatment of insomnia

It is the first dedicated Phase 3 polysomnography study for the treatment of insomnia in people having mild-to-average Alzheimer’s disease and dementia Pharmaceutical company Merck, also known as MSD outside Canada and the United Sta....

Unichem Lab gets tentative nod from USFDA for hydrochloride medicines

These tablets are indicated for nasal decongestant and antihistamine Unichem may produce and market the generic drug products after approval Reports confirm that Unichem Laboratories has been granted a tentative ANDA approval by the Unite....

Roche, Bio-Techne extend collaboration over mRNA ISH tissue analysis

Roche’s new detection kits have more translucent dyes which are suited for mRNA ISH co-localization studies Swiss healthcare company Roche has recently announced that it has expanded its collaboration with Bio-Techne by providing dru....

Esperion confirms FDA acceptance of two NDAs for regulatory review

The NDAs are for oral therapies developed as medication for patients with raised LDL-C who require additional LDL-C lowering Esperion has recently announced that the U.S. Food and Drug Administration has officially accepted both bempedoic ....

Sinclair to buy 21 Disney Sports networks in a deal worth over $10bn

Sinclair Broadcast Group, the American telecommunications giant, has reportedly reached a deal worth over $10 billion in order to purchase as many as 21 regional sports networks from the entertainment conglomerate, The Walt Disney Company. ....

Innovation Pharma obtains FDA guidance for Brilacidin Phase 3 program

Brilacidin oral rinse is supposedly being developed as part of FDA Fast Track designation for Oral Mucositis Reports confirm that Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, has recently received End-of-Phase 2 ....

Cerevance successfully completes Phase 1 clinical trial of CVN424

Clinical stage biopharmaceutical company Cerevance has reportedly completed its Phase 1 clinical trial of CVN424, the company’s first-in-class, oral drug in development for treating Parkinson’s disease. The clinical study effect....

EU CHMP recommends LYNPARZA as first-line treatment for ovarian cancer

AstraZeneca & Merck’s LYNPARZA has reportedly received a positive opinion from the EMA’s (European Medicine Agency) CHMP (Committee for Medicinal Products for Human Use), for the first-line maintenance treatment of the BRCA-....

TAQAs ADC to acquire Middle East drilling rigs of Schlumberger

The acquisition has followed on from fast-tracked expansion activity of ADC in 2018. Saudi Arabia's Industrialisation and Energy Services Company (TAQA), has reportedly announced that Arabian Drilling Company (ADC), its drilling subsid....

Apis Partners to invest in L&T IFD, aims for a 25% stake worth $110M

Apis Partners has signed a binding agreement for the acquisition of the stake and will be investing through one of its funds called Apis Growth Fund II. UK-based venture capital firm Apis Partners has reportedly announced plans to acquire ....